BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sarah Aebersold Sells 2,695 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 2,695 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $25.44, for a total transaction of $68,560.80. Following the completion of the sale, the insider now directly owns 43,165 shares of the company’s stock, valued at approximately $1,098,117.60. This represents a 5.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Sarah Aebersold also recently made the following trade(s):

• On Friday, March 14th, Sarah Aebersold sold 5,632 shares of BioLife Solutions stock. The stock was sold at an average price of $24.96, for a total transaction of $140,574.72.
• On Tuesday, March 11th, Sarah Aebersold sold 1,091 shares of BioLife Solutions stock. The stock was sold at an average price of $25.00, for a total transaction of $27,275.00.
• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $6,484.80.

BioLife Solutions Trading Down 2.3 %

Shares of BLFS stock traded down $0.59 during trading hours on Tuesday, reaching $25.33. 376,894 shares of the stock traded hands, compared to its average volume of 348,703. BioLife Solutions, Inc. has a 1-year low of $14.84 and a 1-year high of $29.55. The business has a fifty day moving average price of $26.56 and a 200 day moving average price of $25.49. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $1.19 billion, a PE ratio of -23.90 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The business had revenue of $22.71 million for the quarter, compared to analyst estimates of $21.73 million. During the same quarter in the previous year, the business earned ($0.21) earnings per share. On average, equities research analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. HC Wainwright upped their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. Benchmark reaffirmed a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research note on Thursday, December 19th. Northland Securities increased their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday, January 8th. Finally, KeyCorp increased their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat, BioLife Solutions presently has an average rating of “Moderate Buy” and a consensus target price of $29.86.

Institutional Investors Weigh In On BioLife Solutions

A number of large investors have recently made changes to their positions in BLFS. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in BioLife Solutions by 13.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,686 shares of the medical equipment provider’s stock valued at $1,835,000 after buying an additional 8,258 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in BioLife Solutions in the 4th quarter valued at approximately $31,000. Point72 Asset Management L.P. acquired a new position in BioLife Solutions in the 4th quarter valued at approximately $11,113,000. ProShare Advisors LLC acquired a new position in BioLife Solutions in the 4th quarter valued at approximately $282,000. Finally, Millennium Management LLC increased its stake in BioLife Solutions by 49.1% in the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock valued at $29,733,000 after buying an additional 377,111 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.